M21-1 and 38 CFR changes, week of Aug 24, 2026

Added

• Use the table below to determine when SC for pathology associated with claimed fibrocystic breast disease is warranted, as well as the proper DC to use in the evaluation.
• residuals of surgery under appropriate DC(s) including
• series for scars, and/or
• a nexus between the fibrocystic breasts with associated atypical hyperplasia and the development of breast cancer
• breast cancer and/or residuals under appropriate DC(s) including
• , no more than a noncompensable evaluation can be assigned as there is no significant alteration in size or form, since the removal of excess tissue results in a return to breast size within normal limits for a human male.

Removed

• Use the table below to determine when SC for pathology associated with claimed fibrocystic breast disease is warranted as well as the proper DC to use in the evaluation.
• residuals of surgery under appropriate DCs including
• series for scars, and
• nexus between the fibrocystic breasts with associated atypical hyperplasia and the development of breast cancer
• breast cancer and/or residuals under appropriate DCs including
• , no more than a noncompensable evaluation can be assigned as there is no significant alteration in size or form since the removal of excess tissue results in a return to breast size within normal limits for a human male.

Added

• due process and
• Legal Instrument Examiner (LIE), and
• Notices from Field Examiners may be considered first party notices when reported on a fully complete
• other possible sources
• computer application used by VA.

and 5 more added passages

Removed

• due process and the
• due process and VA
• Legal instrument examiner (LIE), and
• Notices from field examiners may be considered first party notices when reported on a fully complete
• Other possible sources
• Share computer application.

and 4 more removed passages